Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure  by Shyu, Kou-G.i et al.
Acetylcysteine Protects Against Acute
Renal Damage in Patients With Abnormal
Renal Function Undergoing a Coronary Procedure
Kou-Gi Shyu, MD, PHD, FACC, Jun-Jack Cheng, MD, PHD, Peiliang Kuan, MD, FACC
Taipei, Taiwan
OBJECTIVES We sought to evaluate the efficacy of the antioxidant acetylcysteine in limiting the
nephrotoxicity after coronary procedures.
BACKGROUND The increasingly frequent use of contrast-enhanced imaging for diagnosis or intervention in
patients with coronary artery disease has generated concern about the avoidance of
contrast-induced nephrotoxicity (CIN). Reactive oxygen species have been shown to cause
CIN.
METHODS We prospectively studied 121 patients with chronic renal insufficiency (mean [SD] serum
creatinine concentration 2.8  0.8 mg/dl) who underwent a coronary procedure. Patients
were randomly assigned to receive either acetylcysteine (400 mg orally twice daily) and 0.45%
saline intravenously, before and after injection of the contrast agent, or placebo and 0.45%
saline. Serum creatinine and blood urea nitrogen were measured before, 48 h and 7 days after
the coronary procedure.
RESULTS Seventeen (14%) of the 121 patients had an increase in their serum creatinine concentration
of at least 0.5 mg/dl at 48 h after administration of the contrast agent: 2 (3.3%) of the 60
patients in the acetylcysteine group and 15 (24.6%) of the 61 patients in the control group
(p  0.001). In the acetylcysteine group, the mean serum creatinine concentration decreased
significantly from 2.8  0.8 to 2.5  1.0 mg/dl (p  0.01) at 48 h after injection of the
contrast medium, whereas in the control group, the mean serum creatinine concentration
increased significantly from 2.8  0.8 to 3.1  1.0 mg/dl (p  0.01).
CONCLUSIONS Prophylactic oral administration of the antioxidant acetylcysteine, along with hydration,
reduces the acute renal damage induced by a contrast agent in patients with chronic renal
insufficiency undergoing a coronary procedure. (J Am Coll Cardiol 2002;40:1383–8)
© 2002 by the American College of Cardiology Foundation
Contrast nephropathy is a known risk of coronary interven-
tion (1,2). Significant improvements in interventional tech-
niques and procedures have markedly reduced the risks of
periprocedural complications (3,4). Ongoing advances in
catheter-based technologies for the treatment of coronary
artery disease (CAD) have resulted in a steady increase in
the volume of percutaneous coronary interventional proce-
dures. Patients with renal disease frequently also have severe
CAD and are referred for percutaneous coronary interven-
tion (PCI). Therefore, the renal complications of PCI have
an increasingly important role as a cause of periprocedural
morbidity and mortality (5). The likelihood of contrast
nephropathy occurring is closely related to pre-existing renal
dysfunction and the dose of contrast agent used (6,7). The
best approach to contrast nephropathy is prevention. How-
ever, prevention or mitigation of renal failure after the
administration of contrast agent has been difficult to obtain.
Hydration has been reported to ameliorate contrast ne-
phropathy in patients with chronic renal dysfunction (8).
Administration of drugs such as calcium antagonists, the-
ophylline, dopamine, and atrial natriuretic peptide does not
prevent contrast-induced nephropathy (CIN) (9–13).
Contrast agents reduce renal function by altering renal
hemodynamics and exerting direct toxic effects on tubular
epithelial cells (14). Renal free-radical production increases
after the administration of a contrast agent (15). Although
the pathogenesis of CIN is not fully understood, reactive
oxygen species have a role in CIN (15–17). In animal
studies, superoxide dismutase, a scavenger of reactive oxy-
gen species, prevents renal damage by contrast agents (15).
Recently, Tepel et al. (16) reported that acetylcysteine, an
antioxidant, prevents contrast-induced renal damage in
patients with renal insufficiency undergoing elective com-
puted tomography, and Diaz-Sandoval et al. (17) reported
the beneficial effect of acetylcysteine in patients undergoing
cardiac catheterization. The contrast volume used during
coronary interventional procedures is greater than that used
during computed tomography or diagnostic catheterization.
The procedure time for coronary interventional procedures
is also longer than that for computed tomography and
diagnostic catheterization. It is not known whether acetyl-
cysteine has the same protective effect in patients with renal
dysfunction undergoing PCI. Therefore, we conducted a
prospective, placebo-controlled, randomized trial to study
the protective effects of the antioxidant acetylcysteine on
contrast-induced renal damage in patients with severe
chronic renal insufficiency who underwent elective diagnos-
tic catheterization and PCI.
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METHODS
Patients. Patients scheduled for cardiac angiography who
had serum creatinine concentrations 2.0 mg/dl and 6.0
mg/dl or rates of creatinine clearance (CrCl) 40 ml/min
and 8 ml/min, calculated on the basis of their serum
creatinine concentration, weight, age, and gender (18), were
eligible for the study. Only patients known to have a history
of chronic renal failure and with stable serum creatinine
concentrations were studied. Stable serum creatinine con-
centration was defined as a difference of 0.1 mg/dl
between baseline serum creatinine at 12 to 24 h before
coronary angiography and serum creatinine measured one to
two weeks before angiography. The indications for coronary
angiography were determined by each patient’s cardiologist.
Most patients were studied because of symptomatic coro-
nary ischemia. Exclusion criteria included acute myocardial
infarction requiring primary or rescue coronary intervention,
use of vasopressors before the procedure, cardiogenic shock,
current peritoneal dialysis or hemodialysis, planned post-
contrast dialysis, or allergies to the study medications.
Patients were not allowed to take medications that may
elevate serum creatinine, independent of changes in the
glomerular filtration rate. Both the cardiologist and patient
were not aware of the treatment status. The protocol was
approved by the local Ethics Committee, and all patients
gave written, informed consent.
Study protocol. The patients were randomly assigned to
receive either the antioxidant acetylcysteine and intravenous
saline before and after administration of the contrast agent
(acetylcysteine group) or placebo and saline (control group).
Acetylcysteine was given orally at a dose of 400 mg twice a
day, on the day before and on the day of coronary angiog-
raphy, for a total of two days. Saline (0.45%) was given
intravenously at a rate of 1 ml/kg body weight per hour for
12 h before and 12 h after angiography. All patients were
encouraged to drink if they were thirsty. Serum creatinine
and blood urea nitrogen (BUN) were measured 12 to 24 h
before angiography, 48 h after, and 7 days after coronary
angiography. None of the patients received theophylline,
dopamine, or mannitol during the study. An acute contrast-
induced reduction in renal function was defined as an
increase in the serum creatinine concentration of at least 0.5
mg/dl at 48 h after injection of the radiocontrast medium.
Coronary procedures. Biplane coronary angiography with
or without angioplasty was performed according to standard
clinical practice, using the femoral approach. A 6F catheter
was used for diagnostic coronary angiography, and a 7F
catheter was used for angioplasty. All patients received
iopamidol (Iopamiro, Bracco, Milan, Italy) as their contrast
agent. The iopamidol content was 0.755 mg/ml, and the
iodine content was 370 mg/ml. The dose of contrast agent
was decided by each patient’s cardiologist. Patients who
underwent coronary angioplasty received a bolus of 10,000
U heparin during the procedure, followed by an additional
bolus, if deemed necessary.
Statistical analysis. For a study with a power (1  ) of
90%, a two-sided type I error () of 0.05, and an expected
absolute difference of 0.6 mg/dl in serum creatinine at 48 h,
with a standard deviation of 1.0 mg/dl between the acetyl-
cysteine and control groups, we calculated that we had to
enroll 58 patients in each group.
Data are expressed as the mean value  SD. Categorical
variables were analyzed by the Fischer exact test. Differences
in serum creatinine concentrations between the groups were
analyzed by the Student t test. Differences in serum creat-
inine and BUN before and 48 h after coronary angiography
in the same group were analyzed by the paired t test.
Multiple logistic regression analysis was used to examine the
effect of acetylcysteine, with adjustment for baseline blood
pressure, the presence or absence of diabetes, and baseline
serum creatinine. Analyses were performed with SPSS
software (release 8.0, Chicago, Illinois). All statistical tests
were two-sided. P values 0.05 were considered as statis-
tically significant.
RESULTS
Patient population. A total of 121 patients were enrolled.
Their clinical and biochemical characteristics are shown in
Table 1. The number of patients with diabetes mellitus,
hypertension, or hyperlipidemia was similar in each group,
as was the number receiving diuretics, calcium-channel
antagonists, or angiotensin-converting enzyme inhibitors
before coronary angiography. There were eight diabetic
patients in the acetylcysteine group and six diabetic patients
in the control group who required treatment with insulin.
The volume of contrast agent in both groups was similar.
The number of coronary angiograms or angioplasty proce-
dures in both groups was also similar. The mean weight of
the patients was similar at the start of the study (acetylcys-
teine group: 68  10 kg; control group: 68  9 kg) and at
48 h after coronary angiography (acetylcysteine group: 69
10 kg; control group: 69  9 kg), suggesting a similar fluid
status.
Changes in renal function. The mean serum creatinine
concentration for all patients was 2.8  0.8 mg/dl. The
mean serum creatinine and BUN concentrations and esti-
mated CrCl were similar in each group before contrast
agents were injected. In the control group, the mean serum
creatinine concentration significantly increased from 2.8 
0.8 to 3.1  1.0 mg/dl at 48 h after injection of the contrast
agent (p  0.01). The mean BUN concentration also
significantly increased from 42  16 to 49  23 mg/dl at
Abbreviations and Acronyms
BUN  blood urea nitrogen
CAD  coronary artery disease
CIN  contrast-induced nephropathy
CrCl  creatinine clearance
PCI  percutaneous coronary intervention
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48 h after injection of the contrast agent (p  0.01). In the
acetylcysteine group, the mean serum creatinine and BUN
concentrations significantly decreased from 2.8  0.8 and
41  11 mg/dl to 2.5  1.0 and 35  14 mg/dl,
respectively, at 48 h after injection of contrast agents (p 
0.01 and p 0.01, respectively). The mean serum creatinine
concentration in the acetylcysteine group was significantly
lower than that in the control group at 48 h and 7 days after
the administration of contrast agents (Fig. 1). The absolute
change in serum creatinine concentration was significantly
greater in the control group than in the acetylcysteine group
(p  0.001) (Table 2).
Effect of acetylcysteine. An acute contrast-induced reduc-
tion in renal function occurred in 17 (13.2%) of the 121
patients: 2 (3.3%) of the 60 patients in the acetylcysteine
group and 15 (24.6%) of the 61 patients in the control group
(p  0.001; relative risk 0.13; 95% confidence interval 0.08
to 0.20) (Table 2). Baseline systolic and diastolic blood
pressure did not influence the findings. Ten of the 16
patients with an acute contrast-induced reduction in renal
function had diabetes mellitus: 2 in the acetylcysteine group
and 8 in the control group. The presence or absence of
diabetes mellitus did not affect the therapeutic efficacy of
acetylcysteine.
In the acetylcysteine group, 18 patients (30%) had a
baseline serum creatinine concentration 3.0 mg/dl, as did
22 patients (36%) in the control group. Among these
patients with an elevated baseline creatinine concentration,
2 (11%) of the 18 patients in the acetylcysteine group and 9
(41%) of the 22 patients in the control group had an acute
contrast-induced reduction in renal function (p  0.05)
(Fig. 2). None of the patients with a serum creatinine
concentration 3 mg/dl in the acetylcysteine group had an
acute reduction in renal function. In the control group,
increases in the serum creatinine concentration after admin-









Age (yrs) 70  7 70  7
Gender (M/F, n) 42/18 40/21
Body mass index (kg/m2) 25.9  4.5 25.9  3.8
Systolic blood pressure (mm Hg) 140  24 138  22
Diastolic blood pressure (mm Hg) 81  14 79  16
Serum creatinine (mg/dl)* 2.8  0.8 2.8  0.8
Blood urea nitrogen (mg/dl)† 41  11 42  16
Estimated CrCl (ml/min)‡ 23.6  10.2 23.1  8.9
Hypertension 42 (70%) 41 (67%)
Diabetes mellitus 38 (63%) 39 (64%)
Hyperlipidemia 28 (47%) 24 (39%)
Diuretic therapy 34 (57%) 34 (56%)
Calcium channel blocker therapy 24 (40%) 27 (44%)
Angiotensin-converting enzyme
inhibitor or angiotensin II
receptor antagonist
24 (40%) 26 (43%)
Dose of contrast agent (ml) 119  3 115  48
Angiolpasty/angiography (n) 43/17 40/21
*To convert from mg/dl to mol/l, multiply by 88.4. †To convert from mg/dl to
mmol/liter, multiply by 0.357. ‡Estimated creatinine clearance: CrCl  (140  age
in years  weight in kg/creatinine in mg/dl  72). CrClmale  1  CrCl;
CrClfemale  0.85  CrCl. There were no significant differences between the groups
(p 0.05 for all comparisons). Data are presented as the mean value SD or number
(%) of patients or control subjects.
Figure 1. Changes in serum creatinine concentration before and after injection of contrast agent in the acetylcysteine and control groups.
Table 2. Absolute Changes in Serum Creatinine Concentrations
After Coronary Procedures and the Incidence of Acute











Change in serum creatinine
48 h after coronary
intervention (mg/dl)*




2 (3.3%) 15 (24.6%) 0.001
*To convert from mg/dl to mol/l, multiply by 88.4. Data are presented as the mean
value  SD or number (%) of patients or control subjects.
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istration of contrast agent were related to the severity of the
serum creatinine concentration before hydration: 9 (41%) of
the 22 patients with a serum creatinine concentration 3
mg/dl and 6 (15%) of the 39 patients with a serum
creatinine concentration between 2 and 3 mg/dl had an
acute contrast-induced reduction in renal function (p 
0.05). One of the 15 patients with an acute reduction in
renal function in the control group finally received contin-
uous ambulatory peritoneal dialysis because of progressive
deterioration of renal function. None of the patients in the
acetylcysteine group received dialysis during the follow-up
period of three months. Although control subjects with a
higher baseline serum creatinine concentration tended to
have CIN, the baseline serum creatinine concentration did
not influence the effect of acetylcysteine in the treatment
group.
DISCUSSION
In this study, we found that prophylactic oral administration
of the antioxidant acetylcysteine reduced the incidence of an
acute reduction in renal function by contrast agent in
patients with abnormal renal function who underwent
coronary angiography with or without intervention. The
development of contrast-induced renal failure after coronary
angiography or intervention, though infrequent, is a serious
complication with significant intermediate and long-term
implications for patient outcome and health-care costs
(2,18). The incidence of acute CIN among patients with
diabetes mellitus has been reported to be 50% to 90% in
patients with severe chronic renal insufficiency (19,20).
Although many methods were used to prevent acute renal
damage by contrast agents, most of the results were disap-
pointing (9–13). How to prevent acute renal damage by
contrast agent injection becomes an important issue, be-
cause the application of PCI to the treatment of CAD has
grown dramatically since the first balloon angioplasty was
performed in 1979. Even small increments in serum creat-
inine can translate into significant increases in morbidity
and mortality (21,22).
An acute contrast-induced reduction in renal function
was defined as an increase in the serum creatinine concen-
tration of at least 0.5 mg/dl at 48 h after injection of contrast
medium (16,19). Such an increase occurred in 13.2% of
patients in our study and in 12% of patients reported by
Tepel et al. (16). The severity of renal insufficiency before
contrast injection was more severe in our study than in that
reported by Telpel et al. (2.8 0.8 vs. 2.4 1.3 mg/dl; p
0.01 by t test). The volume of contrast agent was also larger
in our study (118  50 vs. 75 ml; p  0.01). None of the
patients with a serum creatinine concentration 3.0 mg/dl
in the acetylcysteine group developed an acute reduction in
renal function after a coronary procedure. The incidence of
an acute reduction in renal function in patients with a serum
creatinine concentration 3.0 mg/dl was also significantly
lower in the acetylcysteine group than in the control group
(11% vs. 41%, p  0.05). This finding implies that acetyl-
cysteine protects against acute renal damage induced by
contrast agent not only in patients with moderate renal
insufficiency but also in patients with severe renal insuffi-
ciency. The beneficial effects of acetylcysteine also appear to
extend to elderly patients in our study (mean age 70  7
years). Although previous studies have used antioxidants to
reduce acute renal damage in a small number of patients
with abnormal renal function undergoing cardiac catheter-
ization (17,23,24), the baseline serum creatinine concentra-
tion in those studies was 1.5 mg/dl. In this study, we
enrolled a larger number of patients, assessed patients with
a higher baseline serum creatinine concentration (2.0
mg/dl), and included cardiac catheterization and patients
undergoing PCI.
The contrast volume during cardiac procedures has im-
portant implications for postprocedural renal function. An
average contrast volume of 200 to 350 ml has been reported
in previous studies of coronary interventions (1,25). Coro-
Figure 2. Comparison of the incidence of an acute reduction in renal function in serum creatinine concentration between 2 and 3 mg/dl and 3 mg/dl
in the acetylcysteine (open bars) and control groups (cross-hatched bars).
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nary intervention was performed at the time of diagnostic
catheterization in our study, and left ventriculography was
omitted in most of the patients. This strategy resulted in a
smaller contrast volume (120 ml) used in our study.
Although we have proved the protective effect of acetylcys-
teine during cardiac intervention for patients with severe
renal insufficiency, this same effect may not be extrapolated
to patients who were in need of larger doses of contrast
agents.
Administration of contrast agent increases the hypoxia of
the renal medulla and increases renal free-radical production
(15,26). Acetylcysteine has several potential physiologic
effects on the protection of renal damage: 1) it may reduce
the ability of generated oxygen free radicals to damage cells
by scavenging; 2) it increases the expression of nitric oxide
synthase and improves blood flow; and 3) it inhibits cell
apoptosis (27,28). Acetylcysteine has been used as a thera-
peutic agent in a variety of clinical settings. For example,
acetylcysteine serves as a mucolytic agent in chronic bron-
chitis (29), an antidote in acetaminophen-induced hepato-
toxicity (30), and as an inhibitor of hemorrhagic cystitis
caused by cyclophosphamide and ifosfamide (31).
Study limitations. Limitations of our study include the
small sample size and the fact that it was a single-center
study, which may reduce the power of the study. The study
design, however, did allow us to make acetylcysteine-
specific inferences. Whether different pathologies of renal
disease influence the acetylcysteine effect is not explored,
because the underling etiology of chronic renal insufficiency
in our study was not investigated. Finally, our data are
limited to one week after coronary procedures; the effect of
acetylcysteine on long-term outcomes in patients with
abnormal renal function remains unknown.
Clinical implications. The data presented in this study
suggest that the use of acetylcysteine could be beneficial for
ameliorating the acute renal failure observed during coro-
nary angiography with or without intervention. Our pro-
spective, randomized study showed that the beneficial ef-
fects of acetylcysteine appear to extend to elderly patients
with even more severe chronic renal insufficiency. As sug-
gested by Safirstein et al. (32), because of the low cost of
acetylcysteine and its general availability, ease of adminis-
tration, and limited side effects, the use of acetylcysteine to
reduce acute renal failure induced by contrast agents should
be encouraged. Enhanced physician awareness of the renal
implications of PCI, in conjunction with careful patient
selection, risk assessment, and the use of acetylcysteine, will
help to minimize the incidence of renal failure and the
associated increases in morbidity, mortality, and health-care
costs.
Conclusions. We conclude that prophylactic oral admin-
istration of the antioxidant acetylcysteine, along with hy-
dration, reduces acute renal damage induced by contrast
agents in patients with chronic renal insufficiency undergo-
ing a coronary procedure. Because acetylcysteine can de-
crease the incidence of nephrotoxicity after coronary proce-
dures, the general use of acetylcysteine to prevent acute renal
damage in patients with abnormal renal function treated
with a coronary procedure may be warranted.
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